steven galetta

Prof. steven galetta

New York University Langone Medical Center, New York, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
RVRachel E Ventura
Rachel E Ventura
LBLaura J Balcer
Laura J Balcer
SGsteven galetta
steven galetta

1 August 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
SDSiddhant Dogra
Siddhant Dogra
RJRajan Jain
Rajan Jain
MCMeng Cao
Meng Cao
SBSeda Bilaloglu
Seda Bilaloglu
DZDavid Zagzag
David Zagzag
JBJeffrey Berger
Jeffrey Berger

1 September 2020 in Stroke
Verified
Journal Article
Closed access
PDF file
SAShashank Agarwal
Shashank Agarwal
RJRajan Jain
Rajan Jain
SDSiddhant Dogra
Siddhant Dogra
PKPenina Krieger
Penina Krieger
ALAriane Lewis
Ariane Lewis
SGsteven galetta
steven galetta
Background and Purpose: We conducted this study to investigate the prevalence and distribution of cerebral microbleeds and leukoencephalopathy in hospitalized patients with coronavirus disease 2019 (COVID-19) and correlate with clinical, laboratory, and functional outcomes. Methods: We performed a retrospective chart review of 4131 COVID-19 positive adult patients who were admitted to 3 tertiary care hospitals of an academic medical center at the epicenter of the COVID-19 pandemic in New York City from March 1, 2020, to May 10, 2020, to identify patients who had magnetic resonance imaging (MRI) of the brain. We evaluated the MRIs in detail, and identified a subset of patients with leukoencephalopathy and/or cerebral microbleeds. We compared clinical, laboratory, and functional outcomes for these patients to patients who had a brain MRI that did not show these findings. Results: Of 115 patients who had an MRI of the brain performed, 35 (30.4%) patients had leukoencephalopathy and/or cerebral microbleeds. Patients with leukoencephalopathy and/or cerebral microbleeds had neuroimaging performed later during the hospitalization course (27 versus 10.6 days; P <0.001), were clinically sicker at the time of brain MRI (median GCS 6 versus 14; P <0.001), and had higher peak D-dimer levels (8018±6677 versus 3183±3482; P <0.001), lower nadir platelet count (116.9±62.2 versus 158.3±76.2; P =0.03), higher peak international normalized ratio (2.2 versus 1.57; P <0.001) values when compared with patients who had a brain MRI that did not show these findings. They required longer ventilator support (34.6 versus 9.1 days; P <0.001) and were more likely to have moderate and severe acute respiratory distress syndrome score (88.6% versus 23.8%, P <0.001). These patients had longer hospitalizations (42.1 versus 20.9 days; P <0.001), overall worse functional status on discharge (mRS 5 versus 4; P =0.001), and higher mortality (20% versus 9%; P =0.144). Conclusions: The presence of leukoencephalopathy and/or cerebral microbleeds is associated with a critical illness, increased mortality, and worse functional outcome in patients with COVID-19.

18 October 2016 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MWMelissa A. Wilson
Melissa A. Wilson
KGKelly Guld
Kelly Guld
SGsteven galetta
steven galetta
RWRyan D. Walsh
Ryan D. Walsh
JKJulia Kharlip
Julia Kharlip
LFLeslie A. Fecher
Leslie A. Fecher
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs). Case presentation Here we describe a patient treated with ipilimumab who experienced known IrAEs, including hypophysitis, as well as a profound vision loss due to optic neuritis. There are rare reports of optic neuritis occurring as an adverse event associated with ipilimumab treatment. Furthermore, the patient experienced multiple complications from high dose steroids used to manage his IrAEs. Conclusions This case highlights the need for recognition of atypical immune mediated processes associated with newer checkpoint inhibitor therapies including ipilimumab.

1 June 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PBPeter A. Benedict
Peter A. Benedict
NBNatali V. Baner
Natali V. Baner
GHG. Kyle Harrold
G. Kyle Harrold
NMNicholas Moehringer
Nicholas Moehringer
LHLisena Hasanaj
Lisena Hasanaj
LBLaura J. Balcer
Laura J. Balcer

28 October 2002 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
SGsteven galetta
steven galetta
CMClyde Markowitz
Clyde Markowitz
ALAndrew G. Lee
Andrew G. Lee
MULTIPLE SCLEROSIS (MS) is a multifocal, demyelinating disease of the central nervous system (CNS) that is characterized by recurrent or chronically progressive neurologic dysfunction. Multiple sclerosis is first recognized by clinicians as relapsing-remitting MS (RRMS) in most patients.1 Relapsing-remitting MS is characterized by well-defined disease relapses followed by periods of full recovery or with residual deficit on recovery. Although a lack of disease progression between relapses is seen, RRMS may be ongoing subclinically before clinical manifestations. Secondary-progressive MS starts as RRMS and is characterized by gradual disease progression with or without relapses, minor remissions, and plateaus.2 Natural history data suggest that of patients with RRMS at onset, the disease will transform to progressive MS after 10 years in more than 50% and after 25 years in approximately 90%.1